Back to all studies
Active Not RecruitingNCT07043803

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

This study is active but not recruiting. It focuses on schizophrenia and currently lists study information in the United States.

SchizophreniaOtherOver 18 Years
In plain English

Key information made simple

This study is looking at whether a digital support tool can help people with Schizophenia Disorder, schizoaffective disorder, or bipolarity. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Western Behavioral Health of the Alleghenies in Altoona, UPMC Western Behavioral Health at Safe Harbor in Erie, and Western Behavioral Health Mon Yough in McKeesport. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.

Public study data

Key study information

Official title
Reduction of Anticholinergic Medications Project (RAMP) Among Persons With Schizophrenia or Other Psychiatric Disorders Across UPMC Behavioral Healthcare Partner Organizations Using a Stepped-wedge, Randomized Trial Study Design.
Condition
Schizophenia Disorder; Schizoaffective Disorder; Bipolar Disorder; Psychiatric Disorders
Study status
Active Not Recruiting
Sponsor / lead affiliation
University of Pittsburgh
Intervention
Reduction of anticholinergic medication
Location / country
United States
Registry
ClinicalTrials.gov
Why this study may matter

Why this study may matter

This study may matter because it is evaluating Reduction of anticholinergic medication in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.

Before joining

Questions to ask before joining

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT07043803. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may help clarify how this condition is measured or understood.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
University of Pittsburgh
Sponsor type
University
Main activity
digital app or tool
Intervention
Reduction of anticholinergic medication
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Active Not Recruiting
Source
Official registry link
FAQ

Questions about this study

What is Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders?

This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by University of Pittsburgh. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.